A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention
Latest Information Update: 14 Jun 2023
At a glance
- Drugs Atogepant (Primary)
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie; Allergan
- 27 Apr 2023 Results of post hoc analysis the number needed to treat and number needed to harm for atogepant for the preventive treatment of episodic migraine, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
- 28 Sep 2021 According to an AbbVie Media Release, U.S. Food and Drug Administration (FDA) approved QULIPTA™ (atogepant) for the preventive treatment of episodic migraine in adults.The approval is supported by data from a robust clinical program, including NCT03777059, NCT02848326 and NCT03700320.
- 01 Sep 2020 Results published in the Lancet Neurology